Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Jul

Today In Oncology

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Concurrent Palliative Care Remains Underused Among Young Adults With Advanced Cancer

FDA Releases Final Guidances to Expand Participation in Cancer Clinical Trials

Phase III Trial Finds No Benefit for Magrolimab Combination in Higher-Risk MDS

ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC

Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E-Positive Differentiated Thyroid Cancer